| scholarly article | Q13442814 |
| P2093 | author name string | Seung Kew Yoon | |
| Jong Young Choi | |||
| Jung Hyun Kwon | |||
| Kwan Sik Lee | |||
| Kwang Hyub Han | |||
| Seung Woon Paik | |||
| Kwan Soo Byun | |||
| Si Hyun Bae | |||
| Han Chu Lee | |||
| Young Suk Lim | |||
| P2860 | cites work | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. | Q34648995 | ||
| Side effects of therapy of hepatitis C and their management | Q34984142 | ||
| Side effects of therapy for chronic hepatitis C. | Q35133495 | ||
| Peginterferon and ribavirin for chronic hepatitis C. | Q36675912 | ||
| Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. | Q41604120 | ||
| The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. | Q42977771 | ||
| A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan | Q42997693 | ||
| A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group | Q42999978 | ||
| Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis | Q43000773 | ||
| Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. | Q43035294 | ||
| Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha | Q43038357 | ||
| Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
| Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Q43046858 | ||
| Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon | Q43049218 | ||
| Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
| Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea | Q45076673 | ||
| Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a | Q47185597 | ||
| Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. | Q50577281 | ||
| Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C | Q58099679 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | virology | Q7215 |
| ribavirin | Q421862 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 203-211 | |
| P577 | publication date | 2009-08-26 | |
| P1433 | published in | The Korean journal of internal medicine | Q26842387 |
| P1476 | title | Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. | |
| P478 | volume | 24 |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q38433971 | Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin |
| Q44088093 | Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence |
| Q89448325 | Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose |
| Q40706760 | The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. |
Search more.